Weight loss drugs could widen health inequalities without nutritional support

Researchers at UCL and the University of Cambridge argue that weight loss medications such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) risk deepening health inequalities in the UK without proper nutritional and healthcare support. Published in *Nature Medicine*, their study emphasizes that while these drugs have revolutionized obesity treatment, their long-term success depends on access to healthy food, nutrition advice, and ongoing medical care. Between early 2024 and early 2025, an estimated 1.6 million adults in England, Wales, and Scotland used these medications, with an additional 3.3 million expressing interest. However, the cost of Mounjaro alone—£200 per month—makes it unaffordable for many, while healthier diets often come at a higher price, exacerbating food insecurity. Dr. Marie Spreckley, lead author from the University of Cambridge, warns that without equitable support, these treatments could create a 'two-tier system,' where only those with financial and healthcare resources benefit. The study highlights that patients in deprived areas face greater barriers to both medication access and healthy food, despite higher obesity-related illness burdens. Clinical trials show these drugs produce significant weight loss and metabolic improvements, but real-world outcomes may vary widely based on social and economic circumstances. Without proper dietary guidance, side effects like nausea and reduced appetite could lead to poor nutrition or muscle loss. Dr. Adrian Brown, senior author at UCL Medicine, states that obesity treatment is not just medical but also a social and structural issue. The researchers urge policymakers to integrate nutrition support and food affordability measures alongside drug access to ensure equitable health outcomes. Dr. Cara Ruggiero from Cambridge University notes that 12% of UK households face food insecurity, making assumptions about healthy food access unrealistic and inequitable. The authors conclude that without systemic changes, incretin-based therapies could widen rather than reduce health disparities, leaving vulnerable populations behind.